The Impact of 2D Versus 3D Quantitation of Tumor Bulk Determination on Current Methods of Assessing Response to Treatment

Hopper, Kenneth D.; Kasales, Claudia J.; Eggli, Kathleen D.; TenHave, Thomas R.; Belman, N M; Potok, P S; Slyke, Mark A. Van; Olt, George J.; Close, Pamelyn; Lipton, Allan; Harvey, Harold A.; Hartzel, Jonathan

doi:10.1097/00004728-199611000-00011

Cited by 73 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our volumetric approach has the advantage of avoiding areas of necrosis, cysts and surgical cavity, and may potentially estimate tumor size more accurately than linear methods. [15][16][17] With such measurements, volumetric analysis allows for a quantitative method of assessing early tumor change in size that appears to be associated with clinical benefit from bevacizumab treatment. Surprisingly, the same predictive significance of percentage change of enhancing tumor was not observed in a previous study using a volumetric approach.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, recurrent glioblastomas often have imaging components that make traditional measurements challenging including irregular geometry, multifocality, and cystic or necrotic regions. Volumetric methods have the advantage of more reproducibly and precisely measuring the size of tumor, [15][16][17][18] and they are being increasingly used in this setting. For example, volumetric measurement of both the enhancing and nonenhancing tumor have been evaluated as imaging markers for treatment response, 19 PFS, and OS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

Huang

Rahman

Hamdan

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND: Despite a high radiographic response rate in patients with recurrent glioblastoma following bevacizumab therapy, survival benefit has been relatively modest. We assess whether tumor volume measurements based on baseline and early posttreatment MRI can stratify patients in terms of progression-free survival (PFS) and overall survival (OS). METHODS: Baseline (24 1/-4 days) and posttreatment (30 1/-6 days) MRI exams of 91 patients with recurrent glioblastoma treated with bevacizumab were retrospectively evaluated for volume of enhancing tumor as well as volume of the T2/FLAIR hyperintensity. Overall survival (OS) and progression-free survival (PFS) were assessed using volume parameters in a Cox regression model adjusted for significant clinical parameters. RESULTS: In univariable analysis, residual tumor volume, percentage change in tumor volume, steroid change from baseline to posttreatment scan, and number of recurrences were associated with both OS and PFS. With dichotomization by sample median of 52% change of enhancing volume can stratify OS (52 weeks vs. 31 weeks, P 5.013) and PFS (21 weeks vs. 12 weeks, P 5.009). Residual enhancing volume, dichotomized by sample median of 7.8 cm 3 , can also stratify for OS (64 weeks vs. 28 weeks, P <.001) and PFS (21 weeks vs. 12 weeks, P 5.036). CONCLUSIONS: Volumetric percentage change and absolute early posttreatment volume of enhancing tumor can stratify survival for patients with recurrent glioblastoma receiving bevacizumab therapy. Cancer 2013;119:3479-88.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

Huang

Rahman

Hamdan

et al. 2013

Cancer

View full text Add to dashboard Cite

show abstract

“…All statistical analyses were performed by using Stata Release 14.1 software (StataCorp, College Station, having either SD or PD were coded as nonresponders (23)(24)(25).…”

Section: Patient Characteristicsmentioning

confidence: 99%

Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome

Aghighi¹,

Boe²,

Rosenberg³

et al. 2016

Radiology

View full text Add to dashboard Cite

Purpose:To compare the agreement of three-dimensional (3D) tumor measurements for therapeutic response assessment of Ewing sarcoma according to the Children's Oncology Group (COG) criteria, one-dimensional (1D) Response Evaluation Criteria in Solid Tumors (RECIST), and two-dimensional (2D) measurements defined by the World Health Organization (WHO) with tumor volume measurements as the standard of reference and to determine which method correlates best with clinical outcomes. Materials andMethods:This retrospective study was approved by the institutional review board of three institutions. Seventy-four patients (mean age 6 standard deviation, 14.5 years 6 6.5) with newly diagnosed Ewing sarcoma treated at three medical centers were evaluated. Primary tumor size was assessed on pre-and posttreatment magnetic resonance images according to 1D RECIST, 2D WHO, and 3D COG measurements. Tumor responses were compared with the standard of reference (tumor volume) on the basis of RECIST, COG, and WHO therapeutic response thresholds. Agreement between the percentage reduction measurements of the methods was assessed with concordance correlation, Bland-Altman analysis, and Spearman rank correlation. Agreement between therapeutic responses was assessed with Kendall tau and unweighted k statistics. Tumor responses were compared with patient survival by using the log-rank test, Kaplan-Meier plots, and Cox regression. Results:Agreement with the reference standard was significantly better for 3D measurement than for 1D and 2D measurements on the basis of RECIST and COG therapeutic response thresholds (concordance correlation of 0.41, 0.72, and 0.84 for 1D, 2D, and 3D measurements, respectively; P , .0001). Comparison of overall survival of responders and nonresponders demonstrated P values of .4133, .0112, .0032, and .0027 for 1D, 2D, 3D, and volume measurements, respectively, indicating that higher dimensional measurements were significantly better predictors of overall survival. Conclusion:The 3D tumor measurements according to COG are better predictors of therapeutic response of Ewing sarcoma than 1D RECIST or 2D WHO measurements and show a significantly higher correlation with clinical outcomes.q RSNA, 2016

show abstract

“…Com a introdução de novos softwares de reconstrução de imagens multiplanares e 3D, as mensurações volumé-tricas dos tumores passaram a ser consideradas na avaliação da resposta terapêutica. Poucos artigos comparam as duas formas de mensuração, unidimensional e volumétrica (Hopper et al 1996, Sohaib et al 2000, restringindo-se a lesões mais regulares. Sohaib et al (2000) afirmam que há certa limitação na acurácia e reprodutibilidade do método para lesões pequenas.…”

Section: Tomografia Computadorizada De Mastocitomas Em Cãesunclassified

Tomografia computadorizada de mastocitomas em cães: avaliação pré e pós-tratamento quimioterápico

et al. 2013

View full text Add to dashboard Cite

Foram avaliados, por meio da tomografia computadorizada, 19 cães com mastocitomas tratados com quimioterapia. Aspectos como contorno, atenuação, realce pós-contraste e presença de clivagem com estruturas adjacentes foram avaliados. Aplicaram-se os critérios RECIST e a mensuração volumétrica das lesões para se avaliar a resposta ao tratamento. Quanto à atenuação, os mastocitomas se mostraram como lesões homogêneas ou heterogêneas, com tendência a limites definidos e contornos regulares e apresentaram realce moderado após administração do contraste iodado intravenoso. Os métodos RECIST e a mensuração volumétrica apresentaram uma excelente concordância na classificação da resposta terapêutica, fornecendo um bom parâmetro da resposta ao tratamento instituído. O exame de tomografia computadorizada se mostrou útil na delimitação do tumor e importante ferramenta no planejamento das margens cirúrgicas.

show abstract

The Impact of 2D Versus 3D Quantitation of Tumor Bulk Determination on Current Methods of Assessing Response to Treatment

Cited by 73 publications

References 13 publications

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome

Tomografia computadorizada de mastocitomas em cães: avaliação pré e pós-tratamento quimioterápico

Contact Info

Product

Resources

About